ASCO 2024 | Palbociclib, pembrolizumab, and endocrine therapy in HR+/HER2- breast cancer
Alexis Ann LeVee, MD, City of Hope, Duarte, CA, discusses a Phase I/II study (NCT02778685) of palbociclib, pembrolizumab, and endocrine therapy (ET) in patients with HR+/HER2- metastatic breast cancer (MBC). Cohort 1 included patients with stable disease and received palbociclib with ET for at least 6 months, whereas the other two cohorts received combination therapy in the first line setting. A higher overall response rate (ORR) was reported in patients receiving the combination therapy, particularly in the first-line setting. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
